Aurobindo Pharma gained 5.39% to Rs 775.95 at 09:32 IST on BSE after consolidated net profit rose 23.81% to Rs 584.96 crore on 12.42% growth in total income to Rs 3741.79 crore in Q1 June 2016 over Q1 June 2015.
The result was announced after market hours yesterday, 23 August 2016.Meanwhile, the S&P BSE Sensex was up 28.32 points or 0.1% at 28,018.53
On BSE, so far 1.75 lakh shares were traded in the counter as against average daily volume of 1.39 lakh shares in the past one quarter. The stock hit a high of Rs 776.75 and a low of Rs 751.30 so far during the day. The stock had hit a record high of Rs 891.50 on 30 December 2015. The stock had hit a 52-week low of Rs 582 on 25 February 2016.
The large-cap company has equity capital of Rs 58.52 crore. Face value per share is Re 1.
Aurobindo Pharma's earnings before interest, taxation, depreciation and amortization (EBITDA) margin expanded to 23.9% in Q1 June 2016 from 22% in Q1 June 2015. Formulations business rose 15.9% to Rs 3032 crore in Q1 June 2016 over Q1 June 2015. API business rose 1.6% growth to Rs 734.5 crore in Q1 June 2016 over Q1 June 2015.
N. Govindarajan, Managing Director of the company said that with focus on execution and capability enhancements the company continues to progress on specialty generics for a sustained long term growth.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergies and anti-diabetics, supported by an outstanding R&D set-up. The company is marketing these products globally, in over 150 countries.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
